These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26302288)

  • 1. The Challenge of Rare Cancers in Current and Advancing Treatment.
    Houlihan NG
    Oncol Nurs Forum; 2015 Sep; 42(5):566-7. PubMed ID: 26302288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.
    Liu Z; Fang H; Slikker W; Tong W
    Trends Pharmacol Sci; 2016 Oct; 37(10):843-857. PubMed ID: 27461952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accepting risk in the acceleration of drug development for rare cancers.
    Ashley D; Thomas D; Gore L; Carter R; Zalcberg JR; Otmar R; Savulescu J
    Lancet Oncol; 2015 Apr; 16(4):e190-4. PubMed ID: 25846099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare cancers: Challenges & issues.
    Pillai RK; Jayasree K
    Indian J Med Res; 2017 Jan; 145(1):17-27. PubMed ID: 28574010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenges for clinical research on rare tumors in Europe].
    Blay JY
    Bull Acad Natl Med; 2013 Jan; 197(1):103-21; discussion 121-2. PubMed ID: 24672983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving treatment results with reference centres for rare cancers: where do we stand?
    Ray-Coquard I; Pujade Lauraine E; Le Cesne A; Pautier P; Vacher Lavenue MC; Trama A; Casali P; Coindre JM; Blay JY
    Eur J Cancer; 2017 May; 77():90-98. PubMed ID: 28384534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Patel JD; Krilov L; Adams S; Aghajanian C; Basch E; Brose MS; Carroll WL; de Lima M; Gilbert MR; Kris MG; Marshall JL; Masters GA; O'Day SJ; Polite B; Schwartz GK; Sharma S; Thompson I; Vogelzang NJ; Roth BJ
    J Clin Oncol; 2014 Jan; 32(2):129-60. PubMed ID: 24327669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees in Europe: From roots to fruits.
    Coebergh JW; van den Hurk C; Louwman M; Comber H; Rosso S; Zanetti R; Sacchetto L; Storm H; van Veen EB; Siesling S; van den Eijnden-van Raaij J
    Eur J Cancer; 2015 Jun; 51(9):1050-63. PubMed ID: 25934439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Orphan drugs--medications for patients with rare diseases].
    Thielke D; Thyssen JP; Hansen BJ
    Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival from rare cancer in adults: a population-based study.
    Gatta G; Ciccolallo L; Kunkler I; Capocaccia R; Berrino F; Coleman MP; De Angelis R; Faivre J; Lutz JM; Martinez C; Möller T; Sankila R;
    Lancet Oncol; 2006 Feb; 7(2):132-40. PubMed ID: 16455477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H; Liu K; Pariser A; Pazdur R
    Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
    Paciorek CJ; Liu Y;
    Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does orphan drug legislation really answer the needs of patients?
    Haffner ME; Torrent-Farnell J; Maher PD
    Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trial design for rare cancers: why a less conventional route may be required.
    Panageas KS
    Expert Rev Clin Pharmacol; 2015; 8(6):661-3. PubMed ID: 26517109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan diseases, rare diseases, time to get mobilised].
    Cordier JF
    Rev Prat; 2006 Jan; 56(2):123-4. PubMed ID: 16584035
    [No Abstract]   [Full Text] [Related]  

  • 20. Towards government-funded special biomedical research programs to combat rare diseases in China.
    Chen K; Yao L; Liu Z
    Biosci Trends; 2015 Apr; 9(2):88-90. PubMed ID: 25902953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.